Opinion|Videos|May 28, 2025
Preventive Strategies and Emerging Therapies for Bronchiectasis
Panelists discuss how preventing bronchiectasis exacerbations involves understanding a patient’s past exacerbation pattern, implementing comprehensive airway clearance, patient education, and early intervention.
Advertisement
Episodes in this series
Clinical Brief: Preventive Strategies for Bronchiectasis
Main Discussion Topics
- Past exacerbation patterns strongly predict future exacerbations.
- Patient education about early recognition of exacerbations is crucial.
- Understanding the consequences of exacerbations motivates prevention.
Key Points for Physicians
- Review detailed exacerbation history through patient interviews and pharmacy dispensing records.
- Implement and review bronchiectasis action plans at each visit.
- Educate patients about the following:
- Signs and symptoms of exacerbation
- Increasing airway clearance frequency during early exacerbation
- Importance of prompt notification and sputum submission
- Emphasize that exacerbations cause progressive airway damage (“time is lung”)
- Monitor for sarcopenia and nutritional issues, which can worsen outcomes.
Notable Insights
Beyond airway damage, the systemic effects of exacerbations (sarcopenia, nutritional deficits, increased frailty) can significantly impact long-term prognosis, particularly in older patients.
Clinical Significance
A proactive approach to bronchiectasis management emphasizing exacerbation prevention and early intervention can significantly reduce progressive airway damage and systemic complications.
Advertisement
Related to this article
Tammy Lundstrom, MD, JD, discusses the new childhood vaccine order, single-dose MMR access concerns, and the measles resurgence.
Twice-daily dosing of the oral JAK inhibitor deuruxolitinib nearly tripled response rates over once-daily dosing in severe alopecia areata.
Clinicians pair CD20×CD3 bispecifics with radiotherapy in relapsed B‑cell lymphoma, but data stay sparse—early safety signals prompt trials.
Panelists at NASP inSPire2026 said specialty pharmacies could close clinical trial enrollment gaps by capturing one missed data point.
“I think there’s not a lot of information as to what the process is for individuals who have questions about that,” explains Kerry Rogers, MD.
Across 29,132 surgically treated T1 cases, lymph node metastasis hit 19.2% under age 50 vs 11.1% at 50 and older.
Imlunestrant plus abemaciclib doubled median PFS in patients with ESR1-mutated advanced breast cancer.
Rebisufligene etisparvovec-hopf (Fayuvi; Ultragenyx) is a 1-time gene therapy that addresses the underlying cause of Sanfilippo syndrome type A.
Advertisement
Advertisement
Trending on AJMC
1
COVID-19 or Flu? Symptoms Alone Can't Tell: Tammy Lundstrom, MD, JD
2
Nearly a Decade After CAR T, Medicare’s Cell and Gene Therapy Payment Gap Persists
3
Twice-Daily Deuruxolitinib Outperformes Once-Daily in Severe AA
4
Perceptions About CGMs Among Primary Care Physicians and Endocrinologists
5